Long Ideas - Synergy Pharmaceuticals (NASDAQ:SGYP) recently submitted an IND (Investigational New Drug application) for its IBD (inflammatory bowel disease) treatment, SP-333, and is on track to meet … Continue Reading
Read NowLong Ideas - Reports from Bloomberg that Amarin Corp. (NASDAQ:AMRN) has pulled out of the UBS Global Life Sciences Conference next week is leading some analysts to the … Continue Reading
Read NowLong Ideas - Updates from two clinical trials are playing into shares of Oncolytics Biotech (NASDAQ:ONCY) Thursday morning, with some good news perking up the shares after Wednesday’s … Continue Reading
Read NowLong Ideas - Sucampo Pharmaceuticals (NASDAQ:SCMP) announced Wednesday that its lead drug, Amitiza, received approval for marketing in the U.K. for chronic idiopathic constipation (CIC). This marks the … Continue Reading
Read NowLong Ideas - Amarin Corp. (NASDAQ:AMRN) is under pressure for a second day on investor concerns related to the FDA pushing back a decision on NCE status for … Continue Reading
Read NowLong Ideas - The FDA’s Cardiovascular and Renal Drugs Advisory Committee (CRDAC) will meet this Thursday to discuss the NDA for Cornerstone Therapeutics’ (NASDAQ:CRTX) lixivaptan for the treatment … Continue Reading
Read NowLong Ideas - Amarin (NASDAQ:AMRN) announced on Monday that it is unlikely Vascepa’s regulatory exclusivity will be listed in the August Orange Book supplement, due out in mid-September. … Continue Reading
Read Now